Jump to contentJump to search

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Rolfes et al., Neurol Neuroimmunol Neuroinflamm. 2021

Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, Christopher Nelke, Anke Lux, Refik Pul, Christoph Kleinschnitz, Konstanze Kleinschnitz, Rebeca Rogall, Katrin Pape, Stefan Bittner, Frauke Zipp, Clemens Warnke, Yasemin Goereci, Michael Schroeter, Jens Ingwersen, Orhan Aktas, Luisa Klotz, Tobias Ruck, Heinz Wiendl, Sven G Meuth.

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. PubMed ID: 34261812

 

Further Information:

PubMed

Orhan Aktas

Kategorie/n: NND-Publikationen
Responsible for the content: